EYPT241018P17500
- 8.00
- 0.000.00%
EyePoint Pharmaceuticals Newsroom
Further Weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) Drops 12% This Week, Taking Five-year Losses to 54%
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
EyePoint Pharmaceuticals Announces Board Changes and New Appointments
Express News | EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Jefferies Initiates EyePoint Pharmaceuticals at Buy
Karen Zaderej Spends US$100k Buying EyePoint Pharmaceuticals Shares
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates
Express News | JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
EyePoint Pharmaceuticals Analyst Ratings
Express News | EyePoint Pharmaceuticals Inc : JP Morgan Cuts Target Price to $29 From $32
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Express News | EyePoint Pharmaceuticals Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing
EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Optimistic 'Buy' Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Prospects
EyePoint Pharmaceuticals Earns Buy Rating on Duravyu's Promising Efficacy and Safety Profile